T he Diabetes Prevention Program (DPP) was a multicenter (27 clinical centers around the United States) clinical trial aimed at investigating whether modest weight loss through dietary changes and increased physical activity or treatment with an oral diabetes medication metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in people who were overweight and had a higher than normal blood sugar level (but not high enough for a diagnosis of diabetes). Such a condition is called impaired glucose tolerance (IGT) or prediabetes. A total of 3234 people who were overweight, were over the age of 25, had a body mass index greater than 24kg/m 2 , had been diagnosed with IGT, and were from various racial and ethnic populations participated in the program. Participants were randomly assigned into 4 different treatment groups. The first group received an intensive lifestyle intervention in diet, exercise, and behavior modification by eating less fats/calories and exercising 150 minutes per week. Participants in the second group took 850 mg of metformin twice a day. Participants in the third group received placebo pills instead of metformin. Participants in groups two and three received information on diet and exercise, but no intensive counseling. Participants in the fourth group took troglitazone (Rezulin). However, this group was discontinued after 2 years when it was discovered that Rezulin caused serious liver damage. Results of the program indicated that in the end, participants in group one undergoing an intensive lifestyle intervention sharply reduced their chances of developing type 2 diabetes while there was a less dramatic reduction in risk of developing type 2 diabetes among those participants taking metformin. 1 Since the DPP clinical trail ended in 2001, many participants have continued in some type of follow-up program evaluating if they maintained the good results they achieved earlier. Results of the first follow-up studies are scheduled to be published over the next several months. However, study coordinators from the 27 clinical centers across the United States know that millions of Americans could benefit from access to the DPP lifestyle intervention. To date, there is no available national model for dissemination of this beneficial diabetes prevention program. One challenge to the development and implementation of such a model resides in the intensity of the interrvention and cost.
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In this issue of The Diabetes Educator, several authors present programs that have replicated and/or translated results of the DPP into programs demonstrating highly benefical and cost-effective ways to prevent and delay the onset of type 2 diabetes. While there are barriers to implementing evidence-based practice standards, authors provide a wide range of programs related to the DPP along with methods to sustain behavior change and weight loss.
